echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Antitumor Therapy > Clin Cancer Res: Fudan Tumor's new therapy for advanced immunomodulatory triple-negative breast cancer (TNBC) with an effective rate of 95.8%

    Clin Cancer Res: Fudan Tumor's new therapy for advanced immunomodulatory triple-negative breast cancer (TNBC) with an effective rate of 95.8%

    • Last Update: 2022-04-22
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Recently, a Phase II clinical study (FUTURE-C-Plus) was published in the journal Clin Cancer Res.
    The study was led by Prof.
    Zhimin Shao from Fudan University Cancer Hospital.
    ) in the use of Famitinib (famitinib) + camrelizumab (camrelizumab (camrelizumab) + nab-paclitaxel triple regimen treatment efficacy and safety
    .

    Recently, a Phase II clinical study (FUTURE-C-Plus) was published in the journal Clin Cancer Res.
    The study was led by Prof.
    Zhimin Shao from Fudan University Cancer Hospital.
    ) in the use of Famitinib (famitinib) + camrelizumab (camrelizumab (camrelizumab) + nab-paclitaxel triple regimen treatment efficacy and safety
    .


    This is an open-label, single-arm, phase II study of previously untreated patients with advanced immunomodulatory TNBC (CD8 immunohistochemical staining ≥ 10% )
    .


    Eligible patients received oral famitinib 20 mg on days 1-28, camrelizumab 200 mg intravenously on days 1 and 15, and nab - paclitaxel 100 mg/ day intravenously on days 1, 8, and 15 m2, every 4 weeks is a cycle .


    This is an open-label, single-arm, phase II study of previously untreated patients with advanced immunomodulatory TNBC (CD8 immunohistochemical staining ≥ 10% )


    From October 2019 to October 2020, 122 patients were screened in this study, of which 48 (39.


    In the ITT population, the confirmed ORR was 81.
    3% (95% CI, 70.
    2 to 92.
    3), with 5 cases of complete remission and 34 cases of partial remission
    .


    The median treatment-to-response time was 1.


    In the ITT population, the confirmed ORR was 81.


    Median progression-free survival was 13.
    6 months (95% CI, 8.
    4-18.
    8), median OS was not reached (95% CI, NE-NE); OS rate at 12 months was 82.
    6% (71.
    6-93.
    6) , 54.
    4% (36.
    2%-72.
    6%) at 18 months
    .

    Median progression-free survival was 13.
    6 months (95% CI, 8.
    4-18.
    8), median OS was not reached (95% CI, NE-NE); OS rate at 12 months was 82.
    6% (71.
    6-93.
    6) , 54.
    4% (36.
    2%-72.
    6%) at 18 months
    .


    Median progression-free survival was 13.


    Most patients (96% [n = 46]) had at least one treatment-related adverse event (TRAE)
    .


    Grade 3 or 4 TRAEs occurred in 24 (50.


    Most patients (96% [n = 46]) had at least one treatment-related adverse event (TRAE)


    Marker exploration found that the most frequently mutated genes in advanced immunomodulatory TNBC patients were TP53 (78%), BCOR (13%), BRCA1 (13%), KAT6A (13%), and RRM2 (13%)
    .


    In conclusion, KAT6A mutations were positively associated with OR (P = 0.


    Marker exploration found that the most frequently mutated genes in advanced immunomodulatory TNBC patients were TP53 (78%), BCOR (13%), BRCA1 (13%), KAT6A (13%), and RRM2 (13%)


    In conclusion, the study shows that the triple regimen of famitinib + camrelizumab + nab-paclitaxel has significant efficacy and good safety in the treatment of advanced immunomodulatory TNBC
    .

    In conclusion, the study shows that the triple regimen of famitinib + camrelizumab + nab-paclitaxel has significant efficacy and good safety in the treatment of advanced immunomodulatory TNBC
    .
    In conclusion, the study shows that the study shows that the triple regimen of famitinib + camrelizumab + nab-paclitaxel has significant efficacy and good safety in the treatment of advanced immunomodulatory TNBC
    .
    The triple regimen of famitinib + camrelizumab + nab-paclitaxel has significant efficacy and good safety in the treatment of advanced immunomodulatory TNBC
    .

     

    Original source:

    Original source:

    Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY , Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM.
    Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer ( FUTURE-C-PLUS): an open-label, single-arm, phase 2 trial.
    Clin Cancer Res.
    2022 Mar 3:clincanres.
    CCR-21-4313-E.
    2021.
    doi: 10.
    1158/1078-0432.
    CCR- 21-4313.
    Epub ahead of print.
    PMID: 35247906.

    Chen L, Jiang YZ, Wu SY, Wu J, Di GH, Liu GY, Yu KD, Fan L, Li JJ, Hou YF, Hu Z, Chen CM, Huang XY, Cao AY, Hu X, Zhao S, Ma XY , Xu Y, Sun XJ, Chai WJ, Guo X, Chen X, Xu Y, Zhu XY, Zou JJ, Yang WT, Wang ZH, Shao ZM.
    Famitinib with camrelizumab and nab-paclitaxel for advanced immunomodulatory triple-negative breast cancer ( FUTURE-C-PLUS): an open-label, single-arm, phase 2 trial.
    Clin Cancer Res.
    2022 Mar 3:clincanres.
    CCR-21-4313-E.
    2021.
    doi: 10.
    1158/1078-0432.
    CCR- 21-4313.
    Epub ahead of print.
    PMID: 35247906.
    Leave a message here
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.